Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, Créteil, France.
Department of Rheumatology, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France.
Rheumatology (Oxford). 2021 Mar 2;60(3):1243-1251. doi: 10.1093/rheumatology/keaa448.
PsA is a chronic inflammatory arthritis with heterogeneous disease manifestations. Data on the prevalence of PsA in adults differ widely depending on the study and the country. This study aimed to estimate the prevalence and incidence of PsA in France, characterize comorbidities associated to PsA and identify prescribed treatments.
This nationwide cohort study involved the administrative healthcare database (Système National des Données de Santé) of the French health insurance scheme linked to the national hospital discharge database. All adults with PsA registered in the database and identified with a specific International Classification of Diseases, 10th revision code (M07) were included between 1 January 2015 and 31 December 2018.
A total of 63 598 patients were identified as having PsA [55.9 years (s.d. 14.4), 45.6% males]. The prevalence of PsA was estimated at 0.1% and the incidence at 8.4 per 100 000 person-years in the general population. The most common comorbidities were hypertension, diabetes, chronic obstructive pulmonary disease and dyslipidaemia. The prevalence of treatment with conventional synthetic DMARDs (csDMARDs), biological or biosimilar DMARDs (b/bsDMARDs) and apremilast for PsA was 25.9% (16 453), 30.4% (19 325) and 3.5% (2231), respectively. Overall, 8966 (14.1%) patients were new users of csDMARDs, 8311 (13.1%) were new users of b/bsDMARDs and 1529 (7.4%) were new users of apremilast. The most common first-line csDMARD was methotrexate (70.9%) and the most frequent first-line b/bsDMARD was adalimumab (30.8%).
Our results lead to a better understanding of PsA. Results were similar to those from other published studies using other data sources, which highlights the reliability of insurance databases for studies.
PsA 是一种具有多种疾病表现的慢性炎症性关节炎。成人中 PsA 的患病率数据因研究和国家而异，差异很大。本研究旨在估计法国的 PsA 患病率和发病率，描述与 PsA 相关的合并症，并确定所开处方的治疗方法。
这是一项全国性队列研究，涉及法国健康保险计划的管理医疗保健数据库（国家健康数据系统）与国家医院出院数据库相关联。2015 年 1 月 1 日至 2018 年 12 月 31 日期间，数据库中登记且具有特定的国际疾病分类，第 10 版代码（M07）的所有成年 PsA 患者均被纳入研究。
共确定 63598 例患有 PsA[55.9 岁（标准差 14.4），45.6%为男性]。一般人群中 PsA 的患病率估计为 0.1%，发病率为 8.4/100000 人年。最常见的合并症是高血压、糖尿病、慢性阻塞性肺疾病和血脂异常。治疗 PsA 的传统合成 DMARDs（csDMARDs）、生物或生物类似物 DMARDs（b/bsDMARDs）和阿普米司特的使用率分别为 25.9%（16453 例）、30.4%（19325 例）和 3.5%（2231 例）。总体而言，8966 例（14.1%）患者为 csDMARDs 的新使用者，8311 例（13.1%）患者为 b/bsDMARDs 的新使用者，1529 例（7.4%）患者为阿普米司特的新使用者。最常用的一线 csDMARD 是甲氨蝶呤（70.9%），最常用的一线 b/bsDMARD 是阿达木单抗（30.8%）。
我们的研究结果使人们对 PsA 有了更好的了解。结果与使用其他数据源的其他已发表研究相似，这突出了保险数据库在研究中的可靠性。
